论文部分内容阅读
肺表面活性物质是一种保持肺正常功能必须的一种脂类复合物,用以减少肺泡气液面的表面张力,避免肺呼气末的塌陷,Avery和Mead在1959年证实肺表面活性物质缺乏是呼吸窘迫综合征(RDS)发病机制的主要因素。
Pulmonary surfactant is a lipid complex necessary to maintain normal lung function to reduce the surface tension of the alveolar gas-liquid surface and to prevent collapse of the end-expiratory lung. Avery and Mead confirmed in 1959 that pulmonary surfactant Deficiency is a major factor in the pathogenesis of respiratory distress syndrome (RDS).